Beyond sequence similarity: ML-powered identification of pHLA off-targets for TCR-mimic antibodies using high

Alexander Sinclair1, Stefan Krämer1, Christoph Reinhart2

  • 1R&D Department, BioCopy GmbH, Emmendingen, Germany.

Mabs
|December 12, 2025
PubMed

Insights

EpiPredict, a machine learning tool, identifies off-target T-cell receptor mimic (TCRm) antibodies by predicting interactions with peptide-human leukocyte antigen (pHLA) complexes. This advances TCRm immunotherapy safety by detecting sequence-dissimilar cross-reactivity.

Area of Science:

  • Immunology
  • Computational Biology
  • Oncology

Background:

  • T-cell receptor mimic (TCRm) antibodies are crucial for advanced immunotherapies like CAR-T cells.
  • TCRms target peptide-human leukocyte antigen (pHLA) complexes on tumor cells.
  • High specificity is essential for TCRms to prevent off-target toxicity due to low pHLA abundance and sequence similarity.

Purpose of the Study:

  • To develop a novel computational framework for predicting TCRm off-target interactions.
  • To identify cross-reactive peptides with low sequence homology to the intended target.
  • To enhance the preclinical safety assessment of TCRm-based immunotherapies.

Main Methods:

  • Developed EpiPredict, a machine learning framework trained on high-throughput kinetic off-target screening data.
  • EpiPredict learns antibody-specific peptide sequence to binding strength mappings.
  • Applied EpiPredict to TCRms targeting the MAGE-A4 antigen.

Main Results:

  • EpiPredict successfully predicted multiple off-target interactions for MAGE-A4 TCRms.
  • Predicted off-targets exhibited minimal sequence similarity to the intended epitope.
  • Experimental validation confirmed several predicted off-target interactions via T2 cell binding assays.

Conclusions:

  • EpiPredict is a valuable tool for TCRm lead optimization.
  • The framework identifies antibody-specific off-targets missed by traditional peptide-centric methods.
  • EpiPredict supports preclinical de-risking of TCRm-based immunotherapies.

Related Concept Videos